CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
This article was originally published in The Tan Sheet
Executive Summary
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial
You may also be interested in...
Aspirin Use For CVD Prevention Low Among At-Risk Patients – Study
A survey on aspirin use for cardiovascular disease prevention shows low usage "even among patients at increased risk" and could encourage FDA to act on a Bayer's 2003 citizen petition to include a primary prevention indication in professional labeling for aspirin, a researcher says
WHS Findings Back Expanded Aspirin Professional Labeling – Bayer
Results from the Women's Health Study showing the effects of aspirin therapy in women support Bayer Consumer Care's citizen petition requesting expanded professional labeling, the firm says
Bayer Continues Pursuit Of Aspirin Primary MI Prevention Labeling
Bayer is seeking FDA's input on how it can expand professional labeling for aspirin to include a primary myocardial infarction prevention indication